Mesirow Financial Investment Management Inc. Reduces Stock Holdings in Haleon PLC Sponsored ADR (NYSE:HLN)

Mesirow Financial Investment Management Inc. lowered its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 25.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,015 shares of the company’s stock after selling 7,097 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Haleon were worth $216,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the company. XTX Topco Ltd increased its position in shares of Haleon by 33.4% in the first quarter. XTX Topco Ltd now owns 199,348 shares of the company’s stock valued at $2,051,000 after buying an additional 49,897 shares in the last quarter. LPL Financial LLC increased its position in shares of Haleon by 8.3% in the first quarter. LPL Financial LLC now owns 1,256,449 shares of the company’s stock valued at $12,929,000 after buying an additional 95,990 shares in the last quarter. HB Wealth Management LLC increased its position in shares of Haleon by 42.2% in the first quarter. HB Wealth Management LLC now owns 91,594 shares of the company’s stock valued at $943,000 after buying an additional 27,192 shares in the last quarter. Prospect Financial Group LLC increased its position in shares of Haleon by 16.3% in the first quarter. Prospect Financial Group LLC now owns 16,056 shares of the company’s stock valued at $165,000 after buying an additional 2,247 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Haleon by 10.5% in the first quarter. Pacer Advisors Inc. now owns 37,311 shares of the company’s stock valued at $384,000 after buying an additional 3,532 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 2.5%

HLN opened at $9.67 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.98 and a quick ratio of 0.78. The stock has a market capitalization of $43.44 billion, a price-to-earnings ratio of 24.80, a price-to-earnings-growth ratio of 2.73 and a beta of 0.23. The business has a 50-day moving average of $10.37 and a two-hundred day moving average of $10.18. Haleon PLC Sponsored ADR has a 12 month low of $8.86 and a 12 month high of $11.42.

Analyst Upgrades and Downgrades

HLN has been the subject of a number of recent research reports. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. BNP Paribas Exane upgraded Haleon from a “neutral” rating to an “outperform” rating and set a $13.40 price objective for the company in a research report on Tuesday, May 27th. BNP Paribas upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, May 27th. Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price objective for the company in a research report on Friday, May 9th. Finally, Barclays reiterated an “overweight” rating on shares of Haleon in a research report on Tuesday, May 6th. Six investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.